Medtronic, Inc. announced the first patients were enrolled in the Improve SCA Clinical Study, a first-of-its-kind study that will identify patients in developing countries at high risk for sudden cardiac arrest (SCA)–an abrupt loss of heart function that can lead to death in minutes–who have not previously experienced a life threatening arrhythmia (primary prevention patients). The first patients were enrolled at West China Hospital and Fuwai Hospital in China.

Atherotech Diagnostics Lab opened its patient service center in Sarasota, Fla.

Manhattan Scientifics announced a collaboration with Azano Biotech that will make NanoMRX Precision Nanoparticles available for purchase.

Based on its recent analysis of the superconductor technology for MRI market, Frost & Sullivan recognizes Cutting Edge Superconductors, Inc. with the 2013 North American Frost & Sullivan Award for Technology Innovation Leadership.

Aerotel Medical Systems has received the CE Mark approval for its new electrocardiogram (ECG) devices, HeartView P12/8i and HeartView 12L.

Patient enrollment has been completed four months ahead of plan in the Phase III clinical trial EUCLID study for AstraZeneca's ticagrelor (Brilinta) tablets. Part of PARTHENON, AstraZeneca’s largest clinical trial program, EUCLID has randomized more than 13,500 patients globally with peripheral artery disease (PAD); approximately 20 percent are patients in the United States from more than 300 active clinical trial sites across the country. EUCLID is designed to evaluate the effects of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) on cardiovascular (CV) events and safety in PAD patients. Ticagrelor is currently not approved for the treatment of patients with PAD.